Summary
- More than 1,000 patients with advanced breast cancer are denied access to a life-extending drug called Enhertu in the UK.
- NICE, the health assessment body, has deemed Enhertu too expensive for NHS funding.
- Patients and charities criticize the decision, pointing out that Enhertu could provide extra time with loved ones.
- Despite being available in other countries, negotiations between drug companies and NICE have not resulted in approval for NHS funding.